{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:23:45Z","timestamp":1777983825256,"version":"3.51.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Singapore Ministry of Health\u2019s National Medical Research Council"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-026-01298-8","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:39:44Z","timestamp":1772037584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Machine learning integration of serial blood biomarkers enhances cognitive decline prediction in early Parkinson\u2019s disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Raziyeh","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel Y. E.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayne Y.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeline S. L.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dede L.","family":"Heng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shermyn","family":"Neo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay-Yaw","family":"Tay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wing-Lok","family":"Au","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eng-King","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis C. S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Greene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Liakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Ehsan","family":"Saffari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"1298_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely, M. A. et al. The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov. Disord. 23, 837\u2013844 (2008).","journal-title":"Mov. Disord."},{"key":"1298_CR2","doi-asserted-by":"crossref","unstructured":"Simuni, T. & Sethi K. Nonmotor manifestations of Parkinson\u2019s disease. Ann. Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc. 64, S65\u2013S80 (2008).","DOI":"10.1002\/ana.21472"},{"key":"1298_CR3","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00415-010-5465-z","volume":"257","author":"O Riedel","year":"2010","unstructured":"Riedel, O. et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson\u2019s disease. J. Neurol. 257, 1073\u20131082 (2010).","journal-title":"J. Neurol."},{"key":"1298_CR4","doi-asserted-by":"crossref","unstructured":"Deng, X. et al. Disease progression in Parkinson\u2019s disease patients with mild cognitive impairment: 5-year longitudinal study from the early Parkinson\u2019s disease longitudinal Singapore (PALS) cohort. Aging (Albany NY) 16, 11491 (2024).","DOI":"10.18632\/aging.206040"},{"key":"1298_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00415-024-12856-6","volume":"272","author":"F Xu","year":"2025","unstructured":"Xu, F. et al. Cerebrospinal fluid tau and disease progression in early Parkinson\u2019s disease: an 8-year longitudinal study. J. Neurol. 272, 61 (2025).","journal-title":"J. Neurol."},{"key":"1298_CR6","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/jnnp-2013-305277","volume":"84","author":"CH Williams-Gray","year":"2013","unstructured":"Williams-Gray, C. H. et al. The CamPaIGN study of Parkinson\u2019s disease: 10-year outlook in an incident population-based cohort. J. Neurol. Neurosurg. Psychiatry 84, 1258\u20131264 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1298_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/ejn.14094","volume":"49","author":"JC Greenland","year":"2019","unstructured":"Greenland, J. C., Williams-Gray, C. H. & Barker, R. A. The clinical heterogeneity of Parkinson\u2019s disease and its therapeutic implications. Eur. J. Neurosci. 49, 328\u2013338 (2019).","journal-title":"Eur. J. Neurosci."},{"key":"1298_CR8","first-page":"183","volume":"8","author":"M Roheger","year":"2018","unstructured":"Roheger, M., Kalbe, E. & Liepelt-Scarfone, I. Progression of cognitive decline in Parkinson\u2019s disease. J. Park Dis. 8, 183\u2013193 (2018).","journal-title":"J. Park Dis."},{"key":"1298_CR9","first-page":"1051","volume":"14","author":"X Deng","year":"2024","unstructured":"Deng, X. et al. Disease Progression of Data-Driven Subtypes of Parkinson\u2019s Disease: 5-Year Longitudinal Study from the Early Parkinson\u2019s Disease Longitudinal Singapore (PALS) Cohort. J. Park Dis. 14, 1051\u20131059 (2024).","journal-title":"J. Park Dis."},{"key":"1298_CR10","first-page":"2076942","volume":"2020","author":"C Fang","year":"2020","unstructured":"Fang, C. et al. Cognition deficits in Parkinson\u2019s disease: mechanisms and treatment. Park Dis. 2020, 2076942 (2020).","journal-title":"Park Dis."},{"key":"1298_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1212\/WNL.60.1.87","volume":"60","author":"JC Pressley","year":"2003","unstructured":"Pressley, J. C. et al. The impact of comorbid disease and injuries on resource use and expenditures in Parkinsonism. Neurology 60, 87\u201393 (2003).","journal-title":"Neurology"},{"key":"1298_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/ana.26410","volume":"92","author":"J Shen","year":"2022","unstructured":"Shen, J. et al. Plasma MIA, CRP, and albumin predict cognitive decline in Parkinson\u2019s disease. Ann. Neurol. 92, 255\u2013269 (2022).","journal-title":"Ann. Neurol."},{"key":"1298_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson, N. et al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 74, 557\u2013566 (2017).","journal-title":"JAMA Neurol."},{"key":"1298_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","volume":"13","author":"D Aarsland","year":"2017","unstructured":"Aarsland, D. et al. Cognitive decline in Parkinson disease. Nat. Rev. Neurol. 13, 217\u2013231 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"1298_CR15","first-page":"100313","volume":"12","author":"H Oizumi","year":"2025","unstructured":"Oizumi, H. et al. Associations among blood biomarkers, clinical subtypes, and prognosis in Parkinson\u2019s disease. Clin. Park Relat. Disord. 12, 100313 (2025).","journal-title":"Clin. Park Relat. Disord."},{"key":"1298_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2174\/0929866043407138","volume":"11","author":"FL Martin","year":"2004","unstructured":"Martin, F. L. et al. \u03b1-Synuclein and the pathogenesis of Parkinson\u2019s disease. Protein Pept. Lett. 11, 229\u2013237 (2004).","journal-title":"Protein Pept. Lett."},{"key":"1298_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti, L. et al. CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol. 18, 573\u2013586 (2019).","journal-title":"Lancet Neurol."},{"key":"1298_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32480-0","volume":"13","author":"P Youssef","year":"2023","unstructured":"Youssef, P. et al. Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson\u2019s disease biomarkers using multiplexed single molecule counting. Sci. Rep. 13, 5217 (2023).","journal-title":"Sci. Rep."},{"key":"1298_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14, 577\u2013589 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"1298_CR20","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jamaneurol.2015.1449","volume":"72","author":"DC B\u00e4ckstr\u00f6m","year":"2015","unstructured":"B\u00e4ckstr\u00f6m, D. C. et al. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol. 72, 1175\u20131182 (2015).","journal-title":"JAMA Neurol."},{"key":"1298_CR21","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/mds.28056","volume":"35","author":"S Lerche","year":"2020","unstructured":"Lerche, S. et al. CSF NFL in a longitudinally assessed PD cohort: age effects and cognitive trajectories. Mov. Disord. 35, 1138\u20131144 (2020).","journal-title":"Mov. Disord."},{"key":"1298_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","volume":"91","author":"M Bacioglu","year":"2016","unstructured":"Bacioglu, M. et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91, 56\u201366 (2016).","journal-title":"Neuron"},{"key":"1298_CR23","doi-asserted-by":"publisher","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","volume":"93","author":"C-H Lin","year":"2019","unstructured":"Lin, C.-H. et al. Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology 93, e1104\u2013e1111 (2019).","journal-title":"Neurology"},{"key":"1298_CR24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1515\/CCLM.2006.035","volume":"44","author":"B Mollenhauer","year":"2006","unstructured":"Mollenhauer, B. et al. Total tau protein, phosphorylated tau (181p) protein, \u03b2-amyloid1\u201342, and \u03b2-amyloid1\u201340 in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin. Chem. Lab Med 44, 192\u2013195 (2006).","journal-title":"Clin. Chem. Lab Med"},{"key":"1298_CR25","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","volume":"75","author":"A Siderowf","year":"2010","unstructured":"Siderowf, A. et al. CSF amyloid \u03b2 1-42 predicts cognitive decline in Parkinson disease. Neurology 75, 1055\u20131061 (2010).","journal-title":"Neurology"},{"key":"1298_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fnagi.2020.00112","volume":"12","author":"N-C Chen","year":"2020","unstructured":"Chen, N.-C. et al. Plasma levels of \u03b1-synuclein, A\u03b2-40 and T-tau as biomarkers to predict cognitive impairment in Parkinson\u2019s disease. Front Aging Neurosci. 12, 112 (2020).","journal-title":"Front Aging Neurosci."},{"key":"1298_CR27","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/mds.28779","volume":"36","author":"WW Aamodt","year":"2021","unstructured":"Aamodt, W. W. et al. Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease. Mov. Disord. 36, 2945\u20132950 (2021).","journal-title":"Mov. Disord."},{"key":"1298_CR28","first-page":"1117","volume":"11","author":"L-Z Ma","year":"2021","unstructured":"Ma, L.-Z. et al. Serum neurofilament dynamics predicts cognitive progression in de novo Parkinson\u2019s disease. J. Park Dis. 11, 1117\u20131127 (2021).","journal-title":"J. Park Dis."},{"key":"1298_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/ana.22271","volume":"69","author":"AS Chen-Plotkin","year":"2011","unstructured":"Chen-Plotkin, A. S. et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann. Neurol. 69, 655\u2013663 (2011).","journal-title":"Ann. Neurol."},{"key":"1298_CR30","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1021\/acschemneuro.1c00010","volume":"12","author":"M-J Chiu","year":"2021","unstructured":"Chiu, M.-J. et al. Synergistic association between plasma A\u03b21\u201342 and p-tau in Alzheimer\u2019s disease but not in Parkinson\u2019s disease or frontotemporal dementia. ACS Chem. Neurosci. 12, 1376\u20131383 (2021).","journal-title":"ACS Chem. Neurosci."},{"key":"1298_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00702-016-1650-2","volume":"124","author":"J Ding","year":"2017","unstructured":"Ding, J. et al. Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson\u2019s disease. J. Neural Transm. 124, 353\u2013360 (2017).","journal-title":"J. Neural Transm."},{"key":"1298_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.parkreldis.2022.06.004","volume":"101","author":"YY Wong","year":"2022","unstructured":"Wong, Y. Y. et al. Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: a systematic review and meta-analysis. Parkinsonism Relat. Disord. 101, 119\u2013128 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1298_CR33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41531-022-00384-x","volume":"8","author":"L Batzu","year":"2022","unstructured":"Batzu, L. et al. Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson\u2019s disease. npj Park Dis. 8, 154 (2022).","journal-title":"npj Park Dis."},{"key":"1298_CR34","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1002\/alz.13560","volume":"20","author":"E Sanchez","year":"2024","unstructured":"Sanchez, E. et al. Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative. Alzheimer\u2019s. Dement 20, 1753\u20131770 (2024).","journal-title":"Alzheimer\u2019s. Dement"},{"key":"1298_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41531-024-00768-1","volume":"10","author":"CC Pedersen","year":"2024","unstructured":"Pedersen, C. C. et al. Serum neurofilament light at diagnosis: A prognostic indicator for accelerated disease progression in Parkinson\u2019s disease. npj Park Dis. 10, 162 (2024).","journal-title":"npj Park Dis."},{"key":"1298_CR36","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1136\/jnnp-2021-328365","volume":"93","author":"N Vijiaratnam","year":"2022","unstructured":"Vijiaratnam, N. et al. Combining biomarkers for prognostic modelling of Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 93, 707\u2013715 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1298_CR37","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson, N. et al. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 76, 791\u2013799 (2019).","journal-title":"JAMA Neurol."},{"key":"1298_CR38","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3988\/jcn.2022.0160","volume":"19","author":"S Yoon","year":"2023","unstructured":"Yoon, S., Kim, M. & Lee, W.-W. Long short-term memory-based deep learning models for screening Parkinson\u2019s disease using sequential diagnostic codes. J. Clin. Neurol. 19, 270 (2023).","journal-title":"J. Clin. Neurol."},{"key":"1298_CR39","doi-asserted-by":"publisher","first-page":"764497","DOI":"10.3389\/fbinf.2021.764497","volume":"1","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Diagnostic AI Modeling and Pseudo Time Series Profiling of AD and PD Based on Individualized Serum Proteome Data. Front Bioinforma. 1, 764497 (2021).","journal-title":"Front Bioinforma."},{"key":"1298_CR40","doi-asserted-by":"publisher","first-page":"889728","DOI":"10.3389\/fnmol.2022.889728","volume":"15","author":"S Lam","year":"2022","unstructured":"Lam, S. et al. Machine learning analysis reveals biomarkers for the detection of neurological diseases. Front Mol. Neurosci. 15, 889728 (2022).","journal-title":"Front Mol. Neurosci."},{"key":"1298_CR41","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1109\/JBHI.2018.2866873","volume":"23","author":"JC V\u00e1squez-Correa","year":"2018","unstructured":"V\u00e1squez-Correa, J. C. et al. Multimodal assessment of Parkinson\u2019s disease: a deep learning approach. IEEE J. Biomed. Heal Inform. 23, 1618\u20131630 (2018).","journal-title":"IEEE J. Biomed. Heal Inform."},{"key":"1298_CR42","doi-asserted-by":"publisher","first-page":"107495","DOI":"10.1016\/j.cmpb.2023.107495","volume":"234","author":"M Junaid","year":"2023","unstructured":"Junaid, M. et al. Explainable machine learning models based on multimodal time-series data for the early detection of Parkinson\u2019s disease. Comput Methods Prog. Biomed. 234, 107495 (2023).","journal-title":"Comput Methods Prog. Biomed."},{"key":"1298_CR43","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.3390\/biomedicines12122758","volume":"12","author":"R Mohammadi","year":"2024","unstructured":"Mohammadi, R. et al. Machine learning for early detection of cognitive decline in parkinson\u2019s disease using multimodal biomarker and clinical data. Biomedicines 12, 2758 (2024).","journal-title":"Biomedicines"},{"key":"1298_CR44","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jad.2023.10.014","volume":"343","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. The association of serum neurofilament light chains with early symptoms related to Parkinson\u2019s disease: a cross-sectional study. J. Affect Disord. 343, 144\u2013152 (2023).","journal-title":"J. Affect Disord."},{"key":"1298_CR45","first-page":"2135","volume":"12","author":"T Welton","year":"2022","unstructured":"Welton, T. et al. Plasma neurofilament light concentration is associated with diffusion-tensor MRI-based measures of neurodegeneration in early Parkinson\u2019s disease. J. Park Dis. 12, 2135\u20132146 (2022).","journal-title":"J. Park Dis."},{"key":"1298_CR46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13024-020-00385-5","volume":"15","author":"ASL Ng","year":"2020","unstructured":"Ng, A. S. L. et al. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson\u2019s disease. Mol. Neurodegener. 15, 33 (2020).","journal-title":"Mol. Neurodegener."},{"key":"1298_CR47","first-page":"571","volume":"12","author":"E Ygland R\u00f6dstr\u00f6m","year":"2022","unstructured":"Ygland R\u00f6dstr\u00f6m, E. et al. Serum neurofilament light chain as a marker of progression in Parkinson\u2019s disease: Long-term observation and implications of clinical subtypes. J. Park Dis. 12, 571\u2013584 (2022).","journal-title":"J. Park Dis."},{"key":"1298_CR48","doi-asserted-by":"publisher","first-page":"e2185","DOI":"10.1212\/WNL.0000000000200338","volume":"98","author":"S Halloway","year":"2022","unstructured":"Halloway, S. et al. Association of neurofilament light with the development and severity of Parkinson disease. Neurology 98, e2185\u2013e2193 (2022).","journal-title":"Neurology"},{"key":"1298_CR49","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00415-023-12117-y","volume":"271","author":"R Ou","year":"2024","unstructured":"Ou, R. et al. Relationship between plasma NFL and disease progression in Parkinson\u2019s disease: a prospective cohort study. J. Neurol. 271, 1837\u20131843 (2024).","journal-title":"J. Neurol."},{"key":"1298_CR50","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/mds.28206","volume":"35","author":"B Mollenhauer","year":"2020","unstructured":"Mollenhauer, B. et al. Validation of serum neurofilament light chain as a biomarker of Parkinson\u2019s disease progression. Mov. Disord. 35, 1999\u20132008 (2020).","journal-title":"Mov. Disord."},{"key":"1298_CR51","doi-asserted-by":"publisher","first-page":"144","DOI":"10.14802\/jmd.16012","volume":"9","author":"K-Y Kwon","year":"2016","unstructured":"Kwon, K.-Y. et al. Cognition and visit-to-visit variability of blood pressure and heart rate in de novo patients with Parkinson\u2019s disease. J. Mov. Disord. 9, 144 (2016).","journal-title":"J. Mov. Disord."},{"key":"1298_CR52","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/gps.4735","volume":"33","author":"M Doiron","year":"2018","unstructured":"Doiron, M. et al. The influence of vascular risk factors on cognitive function in early Parkinson\u2019s disease. Int J. Geriatr. Psychiatry 33, 288\u2013297 (2018).","journal-title":"Int J. Geriatr. Psychiatry"},{"key":"1298_CR53","doi-asserted-by":"publisher","first-page":"e3319","DOI":"10.1002\/brb3.3319","volume":"13","author":"Y Xiao","year":"2023","unstructured":"Xiao, Y. et al. Association between the blood pressure variability and cognitive decline in Parkinson\u2019s disease. Brain Behav. 13, e3319 (2023).","journal-title":"Brain Behav."},{"key":"1298_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","volume":"16","author":"DJ Irwin","year":"2017","unstructured":"Irwin, D. J. et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 16, 55\u201365 (2017).","journal-title":"Lancet Neurol."},{"key":"1298_CR55","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/brain\/awy146","volume":"141","author":"JL Robinson","year":"2018","unstructured":"Robinson, J. L. et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 141, 2181\u20132193 (2018).","journal-title":"Brain"},{"key":"1298_CR56","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaneurol.2016.3338","volume":"73","author":"SN Gomperts","year":"2016","unstructured":"Gomperts, S. N. et al. Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurol. 73, 1334\u20131341 (2016).","journal-title":"JAMA Neurol."},{"key":"1298_CR57","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awr031","volume":"134","author":"Y Compta","year":"2011","unstructured":"Compta, Y. et al. Lewy-and Alzheimer-type pathologies in Parkinson\u2019s disease dementia: which is more important?. Brain 134, 1493\u20131505 (2011).","journal-title":"Brain"},{"key":"1298_CR58","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00702-017-1821-9","volume":"125","author":"KA Jellinger","year":"2018","unstructured":"Jellinger, K. A. Dementia with Lewy bodies and Parkinson\u2019s disease-dementia: current concepts and controversies. J. Neural Transm. 125, 615\u2013650 (2018).","journal-title":"J. Neural Transm."},{"key":"1298_CR59","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"},{"key":"1298_CR60","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/mds.26913","volume":"32","author":"AJ Espay","year":"2017","unstructured":"Espay, A. J. et al. Biomarker-driven phenotyping in Parkinson\u2019s disease: a translational missing link in disease-modifying clinical trials. Mov. Disord. 32, 319\u2013324 (2017).","journal-title":"Mov. Disord."},{"key":"1298_CR61","doi-asserted-by":"publisher","first-page":"625897","DOI":"10.3389\/fneur.2020.625897","volume":"11","author":"SY-E Ng","year":"2021","unstructured":"Ng, S. Y.-E. et al. Physical activity improves anxiety and apathy in early Parkinson\u2019s disease: a longitudinal follow-up study. Front Neurol. 11, 625897 (2021).","journal-title":"Front Neurol."},{"key":"1298_CR62","doi-asserted-by":"publisher","first-page":"20880","DOI":"10.18632\/aging.104111","volume":"12","author":"ACW Yong","year":"2020","unstructured":"Yong, A. C. W. et al. SNCA Rep1 microsatellite length influences non-motor symptoms in early Parkinson\u2019s disease. Aging (Albany NY) 12, 20880 (2020).","journal-title":"Aging (Albany NY)"},{"key":"1298_CR63","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/WAD.0000000000000124","volume":"30","author":"M Canevelli","year":"2016","unstructured":"Canevelli, M. et al. Predicting the rate of cognitive decline in Alzheimer disease: data from the ICTUS study. Alzheimer Dis. Assoc. Disord. 30, 237\u2013242 (2016).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"1298_CR64","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jalz.2016.06.002","volume":"12","author":"N Coley","year":"2016","unstructured":"Coley, N. et al. Evaluating the clinical relevance of a cognitive composite outcome measure: an analysis of 1414 participants from the 5-year GuidAge Alzheimer\u2019s prevention trial. Alzheimer\u2019s. Dement 12, 1216\u20131225 (2016).","journal-title":"Alzheimer\u2019s. Dement"},{"key":"1298_CR65","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.parkreldis.2014.08.002","volume":"20","author":"N Kandiah","year":"2014","unstructured":"Kandiah, N. et al. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson\u2019s disease. Parkinsonism Relat. Disord. 20, 1145\u20131148 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1298_CR66","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000496454","volume":"47","author":"A Faust-Socher","year":"2019","unstructured":"Faust-Socher, A. et al. Responsiveness to change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in non-demented patients with Parkinson\u2019s disease. Dement Geriatr. Cogn. Disord. 47, 187\u2013197 (2019).","journal-title":"Dement Geriatr. Cogn. Disord."},{"key":"1298_CR67","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden, W. J. Index for rating diagnostic tests. Cancer 3, 32\u201335 (1950).","journal-title":"Cancer"},{"key":"1298_CR68","first-page":"11","volume":"1","author":"DJ Stekhoven","year":"2011","unstructured":"Stekhoven, D. J. Using the missForest package. R. Packag 1, 11 (2011).","journal-title":"R. Packag"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01298-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01298-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01298-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:02:13Z","timestamp":1775577733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01298-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1298"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01298-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7107548\/v1","asserted-by":"object"}]},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"87"}}